| Original language | English |
|---|---|
| Pages (from-to) | e1-e4 |
| Journal | Gastroenterology |
| Volume | 155 |
| Issue number | 5 |
| DOIs | |
| State | Published - Nov 2018 |
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Multiomics Analyses to Deliver the Most Effective Treatment to Every Patient With Inflammatory Bowel Disease. / IBD Multi Omics Consortium.
In: Gastroenterology, Vol. 155, No. 5, 11.2018, p. e1-e4.Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Multiomics Analyses to Deliver the Most Effective Treatment to Every Patient With Inflammatory Bowel Disease
AU - IBD Multi Omics Consortium
AU - Weersma, Rinse K.
AU - Xavier, Ramnik J.
AU - Weersma, R. K.
AU - Barrett, J. C.
AU - Vermeire, S.
AU - Xavier, R. J.
AU - Anderson, C. A.
AU - Wijmenga, C.
AU - Daly, M. J.
AU - Alm, E. J.
AU - Raes, J.
AU - Huttenhower, C.
AU - Stappenbeck, T.
AU - Netea, M.
AU - Kaser, A.
AU - Franke, A.
AU - McGovern, D. P.
AU - Colombel, J. F.
AU - van den Brink, G. R.
AU - Uhlig, H. H.
AU - Georges, M.
AU - Lees, C. W.
AU - Parkes, M.
AU - Giallourakis, C.
AU - Hart, A.
AU - Rioux, J. D.
AU - Sokol, H.
AU - Hurtado-Lorenzo, A.
AU - Yeretssian, G.
AU - Markus- de Kwaadsteniet, M. L.
AU - Festen, E. A.
AU - Rahmouni, S.
AU - Vieira-Silva, S.
AU - McIntyre, R. E.
AU - Moutsianas, L.
AU - Vermeire, Severine
AU - Barrett, Jeffrey C.
N1 - Funding Information: Funding The meeting was supported by a grant from the Royal Netherlands Academy of Arts and Sciences . Rinse K. Weersma is supported by a VIDI grant (016.136.308) from the Netherlands Organisation for Scientific Research (NWO) and a Diagnostics Grant from the Dutch Digestive Foundation (D16-14). Funding Information: Conflicts of interest The authors have made the following disclosures: Rinse K. Weersma received research grants from Takeda, Tramedico and Ferring. Severine Vermeire has received grant support from AbbVie, MSD, Pfizer, and Takeda; received speaker fees from AbbVie, MSD, Takeda, Ferring, Dr. Falk Pharma, Hospira, Pfizer Inc, and Tillots; and served as a consultant for AbbVie, MSD, Takeda, Ferring, Genentech/Roche, Shire, Pfizer Inc, Galapagos, Mundipharma, Hospira, Celgene, Second Genome, and Janssen. The remaining authors disclose no conflicts.
PY - 2018/11
Y1 - 2018/11
UR - http://www.scopus.com/inward/record.url?scp=85055839608&partnerID=8YFLogxK
U2 - 10.1053/j.gastro.2018.07.039
DO - 10.1053/j.gastro.2018.07.039
M3 - Article
C2 - 30077628
AN - SCOPUS:85055839608
VL - 155
SP - e1-e4
JO - Gastroenterology
JF - Gastroenterology
SN - 0016-5085
IS - 5
ER -